DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy

Area of Science:

• Oncology
• Molecular Biology
• Radiochemistry

Background:

• Targeted radionuclide therapy (TRT) faces limitations due to cancer cells' ability to survive high radiation doses.
• Tumor heterogeneity and the development of radiation/drug-tolerant cells reduce TRT efficacy.
• Cancer cells possess robust DNA damage response/repair mechanisms that promote survival.

Purpose of the Study:

• To identify potential molecular targets for enhancing future targeted radionuclide therapy (TRT) strategies.
• To explore the role of DNA damage response/repair and maintenance systems in cancer cell survival.
• To propose novel therapeutic approaches by combining TRT with targeted inhibition of cancer survival factors.

Main Methods:

• Review of current literature on cancer genomics, DNA damage response pathways, and TRT.
• Analysis of key factors involved in cancer cell survival and resistance to therapy.
• Identification of potential molecular targets and combination strategies for TRT.

Main Results:

• Cancer cells' inherent DNA repair mechanisms and dysregulated epigenetic systems contribute to TRT resistance.
• Key molecular targets including PARP, ATM/ATR, transcription factors, and DNA methyltransferases are implicated in cancer survival.
• Inhibition of these targets, particularly with non-radioactive agents, shows potential for synergistic effects with TRT.

Conclusions:

• Targeting DNA maintenance factors is a promising strategy to overcome TRT limitations and improve patient outcomes.
• Combining TRT with inhibitors of DNA repair and epigenetic machinery can enhance therapeutic efficacy.
• Future TRT strategies should consider targeting cancer-specific survival mechanisms for improved treatment response.